The US FDA approved on Tuesday a new weight loss drug that will be called Qsymia, the brand name for the combination of two previously approved drugs, phentermine and extended-release topiramate. The drug is manufactured by Vivus, Inc. In a press release, the FDA said Qsymia had been approved for use in obese adults (BMI of 30…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Contrave, the investigational diet pill combination of naltrexone and bupropion, has been granted a possible new lease on life by the FDA. In January of this year, the FDA issued a complete response letter to Orexigen, the drug’s sponsor. Now Orexigen says that it has received guidance from the FDA that could lead to approval of the…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

The experimental diet drug combination of phentermine and topiramate demonstrated “robust efficacy” in  CONQUER, a large new trial published online in the Lancet. The trial’s results come after a year in which the FDA turned down three investigational diet drugs (including Qnexa, the phentermine-topiramate combination used here) and removed the diet drug sibutramine from the…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.